News from Research Center

News from the Center for Pharmaceutical Biotechnology and Nanomedicine:

1. Prof. Torchilin was awarded with the 2013 Blaise Pascal Medal in Biomedical Sciences by the European Academy of Sciences “In recognition of his outstanding contributions into various areas of biomedical sciences, experimental pharmacology, nanomedicine, and pharmaceutical biotechnology”

2. Prof. Torchilin has delivered key-note/plenary talks at the following meetings:

  • 19th International Symposium on Microencapsulation, Pamplona, Spain, September 2013
  • Conference on Nanotechnology for Health, Belo Horizonte, Brazil, November 2013

3. Prof. Torchilin has delivered invited talks at the following meetings:

  • Meeting of Pharmaceutical Societies, Cape Town, South Africa, October 2013
  • Annual AAPS meeting, San Antonio, November 2013
  • International Pharmaceutical Conference, Ribeirao Preto, Brazil, November 2013
  • International Liposome Advances Conference, London, UK, December 2013

4. The following papers have been published:

  1. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety.

Zhu L, Wang T, Perche F, Taigind A, Torchilin VP.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17047-52. PMID: 24062440

 

2.  Gellan gum nanohydrogel containing anti-inflammatory and anti-cancer drugs: A multi-drug delivery system for a combination therapy in cancer treatment.

D’Arrigo G, Navarro G, Di Meo C, Matricardi P, Torchilin V.

Eur J Pharm Biopharm. 2013 Nov 9. [Epub ahead of print] PMID: 24215783

 

3. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.

Apte A, Koren E, Koshkaryev A, Torchilin VP.

Cancer Biol Ther. 2013 Oct 21;15(1). [Epub ahead of print] PMID: 24145298

 

4. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer.

Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, Torchilin VP.

Cancer Lett. 2013 Oct 4. [Epub ahead of print] PMID: 24099916

 

5. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin.

Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP.

J Drug Target. 2013 Dec;21(10):994-1000. PMID: 24098980

 

6. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.

Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, Torchilin VP.

Nanomedicine. 2013 Sep 9. [Epub ahead of print] PMID: 24028893

 

7. Current trends in the use of liposomes for tumor targeting.

Deshpande PP, Biswas S, Torchilin VP.

Nanomedicine (Lond). 2013 Sep;8(9):1509-28. PMID: 23914966

 

 

  • Contact Info

    Department of Pharmaceutical Sciences School of Pharmacy
    Bouvé College of Health Sciences
    Northeastern University
    140 The Fenway
    Boston, Massachusetts 02115

    Find Us
    Contact Us
    Make a gift